Document:

exv10w13

Exhibit 10.13

SHARE REPURCHASE AGREEMENT

Subject to the terms and conditions contained in this agreement (this “Agreement”), RESEARCH
PHARMACEUTICAL SERVICES, INC. F/K/A CROSS SHORE ACQUISITION CORPORATION, a Delaware corporation,
the “Company”), hereby purchases from PANGAEA ONE ACQUISITION HOLDINGS I, LLC ( “Stockholder”), and
Stockholder hereby sells to the Company, 750,000 shares (the “Shares”) of the Company’s common
stock for the cash purchase price of US$4.85 per Share for an aggregate purchase price of
US$3,637,500 (the “Purchase Price”).

Stockholder hereby represents and warrants to the Company that (i) Stockholder has the full power
and authority to enter into, execute, deliver and perform its obligations under this Agreement and
upon execution hereof, this Agreement shall be the binding obligation of Stockholder, (ii)
Stockholder is the record and beneficial owner of the Shares, (iii) Stockholder has good, valid and
marketable title to the Shares and the Shares will be transferred to the Company hereunder free and
clear of all liens, (iv) neither Stockholder nor its affiliates have entered into any contract,
commitment, agreement or arrangement (other than this Agreement) with any person or entity
entitling such other person or entity to purchase any or all of the Shares; and (v) neither the
execution and delivery of this Agreement, nor the consummation of the transactions contemplated
hereby, will (a) violate any constitution, statute, regulation, rule, injunction, judgment, order,
decree, ruling, charge, or other restriction of any governmental authority, court or securities
exchange, as the case may be, to which the Stockholder is subject, (b) violate any provision of the
charter, operating agreement or other governing documents of the Stockholder, or (c) conflict with,
result in a breach of, constitute a default under, result in the acceleration of, create in any
party the right to accelerate, terminate, modify, or cancel, or require any notice or consent under
any contract to which the Stockholder or any of its parent, subsidiaries or affiliates is subject
(or result in the imposition of any lien upon any of its or any of its parent or subsidiaries’
assets).

The Company hereby represents and warrants to Stockholder that (i) the Company has the full power
and authority to enter into, execute, deliver and perform its obligations under this Agreement and
upon execution hereof, this Agreement shall be the binding obligation of the Company and (ii)
neither the execution and delivery of this Agreement, nor the consummation of the transactions
contemplated hereby, will (a) violate any constitution, statute, regulation, rule, injunction,
judgment, order, decree, ruling, charge, or other restriction of any governmental authority, court
or securities exchange, as the case may be, to which the Company is subject, (b) violate any
provision of the charter, bylaws or other governing documents of the Company, or (c) conflict with,
result in a breach of, constitute a default under, result in the acceleration of, create in any
party the right to accelerate, terminate, modify, or cancel, or require any notice or consent under
any contract to which the Company or any of its subsidiaries or affiliates is subject (or result in
the imposition of any lien upon any of its or any of its subsidiaries’ assets). Immediately before
and after the consummation of the transactions contemplated by this Agreement, (A) the Company will
be solvent as such term is contemplated under applicable law and (B) the Company will have
sufficient surplus to pay the Purchase Price in accordance with the laws of the State of Delaware.
Except for disclosure under the rules of the AIM, the Company is not required to give any notice
to, make any filing with, or obtain any authorization, consent, or approval of any governmental
authority in order for the parties to consummate the transactions contemplated by this Agreement.

The Parties each agree that this Agreement, the terms and conditions of this Agreement and the
discussions surrounding the execution and delivery of this Agreement shall be deemed confidential
information and shall not be disclosed or otherwise disseminated by the Parties,
except as otherwise required by applicable law or rules of an applicable exchange, market or
regulatory authority.

Upon execution of this Agreement by the Parties and simultaneously with the delivery by Stockholder
to Capita Registrars, the Company’s registrar (the “Registrar”), of the Closing Documents (as
hereinafter

 

 

defined) (with a copy to be furnished simultaneously to the Company), the Company shall pay the
Purchase Price to Stockholder by wire transfer of immediately available funds to the following
account :

Bank Name: JP Morgan Chase

Bank Address: 1166 Avenue of the Americas, New York, NY 10036

ABA #: [          ]

Account Name: [          ]

Account Number: [          ]

Contemporaneously with the execution and delivery of this Agreement, Stockholder shall (i) execute
and deliver to the Registrar a stock power for the Shares in the form attached hereto as Exhibit A,
(ii) deliver to the Registrar the stock certificate representing the Shares, and (iii) enter into,
execute and deliver a stock transfer form to transfer the record ownership of the Shares from
Stockholder to the Company, in the form attached hereto as Exhibit B (collectively, the “Closing
Documents”).

From and after the payment by the Company to Stockholder of the Purchase Price, Stockholder shall
have no further ownership interest in or any other rights in or to the Shares.

This Agreement shall be governed by the laws of the State of Delaware. This Agreement sets forth
the entire agreement among the parties and their affiliates with respect to the subject matter
hereof and shall supersede all prior and contemporaneous communications, agreements and
understandings, written or oral, with respect thereto. No amendment of any provision of this
Agreement shall be valid unless the same shall be in writing and signed by the parties hereto.
This Agreement may be executed in counterparts and may be executed by facsimile or electronic
copies and such copies shall be treated as originally executed. The parties each agree to execute
such further documents and perform and do such further acts and things following the closing of the
transactions contemplated by this Agreement as the other party may reasonably request in writing in
order to carry the provisions of this Agreement into full force and effect. The costs and expenses
incurred in carrying out any such request shall be paid by the party making the request.

     IN WITNESS WHEREOF, the Parties hereto have executed this Share Repurchase Agreement as of the
dates set forth below.

	 	 	 	 	 
	 	RESEARCH PHARMACEUTICAL SERVICES, INC.

 	 
	 	By:  	/s/ Daniel M. Perlman
 	 
	 	 	Name:  	Daniel M. Perlman  	 
	 	 	Title:  	CEO 	 
	 	 	Date: 	October 4, 2007 	 
	 
	 	PANGAEA ONE ACQUISITION HOLDINGS I, LLC

 	 
	 	By:  	/s/ Peter Yu
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 	 	Date: 	October 4, 2007 	 
	 

-2-

 

Exhibit A

FOR VALUE RECEIVED, Pangaea One Acquisition Holdings I, LLC

hereby sells, assigns and transfers unto

PLEASE INSERT SOCIAL

SECURITY OR OTHER

TAXPAYER IDENTIFYING

NUMBER OF ASSIGNEE

 20-4322769                   
   ReSearch Pharmaceutical Services, Inc.

750,000 shares of common stock of ReSearch Pharmaceutical Services, Inc., standing in its name on
the books of said corporation represented by Certificate No. A00317 and does hereby irrevocably
constitute and appoint Capita IRG Plc to transfer the said stock on the books of the said
corporation with full power of substitution in the premises. Certificate A00317 represents
2,200,000 shares and so the transferor hereby requests that the balance shares be returned to the
transferor by means of a new certificate representing 1,450,000 shares.

Dated as of October 4, 2007

	 	 	 	 	 
	 	Pangaea One Acquisition Holdings I, LLC

 	 
	 	By:  	/s/ Paul Hong
 	 
	 	 	Name:  	Paul Hong  	 
	 	 	Title:  	Assistant Secretary 	 
	 

IN THE PRESENCE OF

                                                                  
              

NOTE: The signature(s) of the assignor(s) must correspond exactly with the name(s) appearing on the
certificate. Transfer Agents may require that the signature(s) of the assignor(s) must be
guaranteed by a commercial bank, trust company or member firm of the Stock Exchange.

-3-

 

Exhibit B

-4-exv10w14

Exhibit 10.14

CONSULTING AGREEMENT

          This Consulting Agreement (this “Agreement”) is made and entered into as of November
16, 2007 by and between RESEARCH PHARMACEUTICAL SERVICES, INC. F/K/A CROSS SHORE ACQUISITION
CORPORATION, a Delaware corporation, (the “Company”) and CARTESIAN CAPITAL MANAGEMENT, LLC
(“Consultant”).

          In consideration of the premises and the mutual covenants contained herein, the parties agree
as follows:

          1. Term. This Agreement shall be in effect for a term commencing on the date hereof
and ending on December 31, 2007 (the “Term”).

          2. Services. Consultant shall perform or cause to be performed the following services
for the Company and its subsidiaries: (i) identification and analysis of potential acquisitions by
the Company or its subsidiaries outside of the United States, with emphasis on opportunities in
Asia and greater Europe, (ii) as reasonably directed by the Company, assist in the negotiation of
definitive acquisition agreements with potential targets, and (iii) as reasonably directed by the
Company, support, negotiation and analysis of financing alternatives, including, without
limitation, in connection with acquisitions, capital expenditures, public offerings, and
refinancing of existing indebtedness. In connection with the performance of the services,
Cartesian represents and warrants to the Company and the Company acknowledges that Cartesian (a)
has the knowledge and expertise in the markets in which the Company operates and in the markets in
which the Company is seeking acquisition targets in order to perform the services set forth in this
Agreement, (b) has, as of the date of this Agreement, already identified potential acquisition
targets for consideration by the Company, and (c) shall during the Term continue to seek and
identify acquisition targets for the Company as provided for in this Agreement.

          3. Advisory Fee. Commencing from the date of this Agreement and continuing through
the expiration of the Term, the Company shall pay to Consultant or its designees an advisory
services fee (the “Advisory Services Fee”) in an amount equal to $600,000. Such Advisory
Services Fee shall be payable by the Company to Consultant on January 3, 2008.

          4. Personnel. Consultant shall provide and devote to the performance of this
Agreement such employees and agents of Consultant as Consultant shall deem reasonably appropriate
and necessary to the furnishing of the services required. The fees specified in this Agreement
shall be payable by the Company to Consultant for the services provided by Consultant pursuant to
this Agreement.

          5. Liability. Neither Consultant nor any of its affiliates or partners, or their
employees or agents shall be liable to the Company or its subsidiaries or affiliates (collectively,
the “Company Group”) for any loss, liability, damage or expense arising out of or in
connection with the performance of services contemplated by this Agreement, unless such loss,
liability,

 

 

damage or expense shall be proven to result directly or indirectly from negligence or willful
misconduct on the part of Consultant, its affiliates, partners, employees or agents. Consultant
makes no representations or warranties, express or implied, in respect of the services to be
provided by Consultant or any of its affiliates, partners, employees or agents. In no event will
any of the parties hereto be liable to any other party hereto for any indirect, special, incidental
or consequential damages, including lost profits or savings, whether or not such damages are
foreseeable, or in respect of any liabilities relating to any third party claims (whether based in
contract, tort or otherwise).

          6. Indemnity. The Company and its subsidiaries shall defend, indemnify and hold
harmless each of Consultant, its affiliates, and its partners, and their employees and agents from
and against any and all loss, liability, damage or expenses arising from any claim by any person
with respect to, or in any way related to, the performance of services contemplated by this
Agreement (including attorneys’ fees) (collectively, “Claims”) resulting from any act or
omission of Consultant, its affiliates, partners, employees or agents, other than for Claims which
shall be proven to be the direct or indirect result of negligence or willful misconduct by
Consultant, its affiliates, partners, employees or agents. The Company and its subsidiaries shall
defend at its own cost and expense any and all suits or actions (just or unjust) which may be
brought against the Company Group and Consultant, its officers, directors, affiliates, partners,
employees or agents or in which Consultant, its affiliates, partners, employees or agents may be
impleaded with others upon any Claims, or upon any matter, directly or indirectly, related to or
arising out of this Agreement or the performance hereof by Consultant, its affiliates, partners,
employees or agents, except that if such damage shall be proven to be the direct or indirect result
of negligence or willful misconduct by Consultant, its affiliates, partners, employees or agents,
then Consultant shall reimburse the Company Group for the costs of defense and other costs incurred
by the Company Group.

          7. Relationship of the Parties. This Agreement is intended to create an independent
contractor relationship between the parties. Nothing stated herein shall be construed as
establishing between the parties the relationship of partners, agency, employer-employee or
co/joint venturers. Each party shall be solely responsible for and shall comply with all state,
federal, and local laws pertaining to employment, taxes, income withholding, unemployment
compensation or contributions and other employment related statutes applicable to that party.
Neither party has the authority to bind the other party and shall not indicate or otherwise hold
itself out as having such authority.

          8. Assignment. Neither party may assign any obligations hereunder to any other party
without the prior written consent of the other party (which consent shall not be unreasonably
withheld); provided, that Consultant may, without consent of the Company, assign its rights
and obligations under this Agreement to any of its affiliates. The assignor shall remain liable
for the performance of any assignee.

          9. Successors. This Agreement and all the obligations and benefits hereunder shall
inure to the successors and assigns of the parties.

2

 

          10. Counterparts. This Agreement may be executed and delivered by each party hereto
in separate counterparts, each of which when so executed and delivered shall be deemed an original
and all of which taken together shall constitute but one and the same agreement.

          11. Entire Agreement; Modification; Governing Law. The terms and conditions hereof
constitute the entire agreement between the parties hereto with respect to the subject matter of
this Agreement and supersede all previous communications, either oral or written, representations
or warranties of any kind whatsoever, except as expressly set forth herein. No modifications of
this Agreement nor waiver of the terms or conditions thereof shall be binding upon either party
unless approved in writing by an authorized representative of such party. All issues concerning
this Agreement shall be governed by and construed in accordance with the laws of the State of New
York, without giving effect to any choice of law or conflict of law provision or rule (whether of
the State of New York or any other jurisdiction) that would cause the application of the law of any
jurisdiction other than the State of New York.

[remainder of page intentionally left blank — signature page to follow]

* * * * *

3

 

          IN WITNESS WHEREOF, the parties have executed this Advisory Agreement as of the date first
written above.

	 	 	 	 	 	 	 
	 	 	RESEARCH PHARMACEUTICAL SERVICES, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Daniel M. Perlman	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	Daniel M. Perlman	 	 
	 

	 	Title:	 	Chief Executive Officer	 	 
	 
	 	 	 	 	 	 
	 	 	CARTESIAN CAPITAL MANAGEMENT, LLC	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Peter Yu	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	Peter Yu	 	 
	 

	 	Title:	 	Managing Member	 	 

Signature Page to 

Consulting Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}]]